2024
The nature of chronic rejection after lung transplantation: a murine orthotopic lung transplant study
Heigl T, Kaes J, Aelbrecht C, Serré J, Yamada Y, Geudens V, Van Herck A, Vanstapel A, Sacreas A, Ordies S, Frick A, Gimenez B, Van Slambrouck J, Beeckmans H, Oztürk N, Orlitova M, Vaneylen A, Claes S, Schols D, Velde G, Schupp J, Kaminski N, Boesch M, Korf H, van der Merwe S, Dupont L, Vanoirbeek J, Godinas L, Van Raemdonck D, Janssens W, Gayan-Ramirez G, Ceulemans L, McDonough J, Verbeken E, Vos R, Vanaudenaerde B. The nature of chronic rejection after lung transplantation: a murine orthotopic lung transplant study. Frontiers In Immunology 2024, 15: 1369536. PMID: 38736881, PMCID: PMC11084670, DOI: 10.3389/fimmu.2024.1369536.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBronchiolitis ObliteransChronic DiseaseDisease Models, AnimalGraft RejectionLungLung TransplantationMaleMiceMice, Inbred C57BLConceptsChronic lung allograft dysfunctionChronic rejectionLung transplantationSingle cell RNASingle cell RNA profilingOrthotopic left lung transplantationComplications post-transplantationLung allograft dysfunctionMouse lung transplantationLeft lung transplantationLung transplantation studiesAllograft dysfunctionPleural infiltrationPost-transplantationBronchiolitis obliteransInnate inflammationChronic complicationsPrimary onsetEndothelial destructionTransplantationDay 7Immunological perspectiveArterial responseTransplantation studiesLung
2023
Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
Gottlieb J, Fischer B, Schupp J, Golpon H. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors. PLOS ONE 2023, 18: e0284653. PMID: 37200246, PMCID: PMC10194991, DOI: 10.1371/journal.pone.0284653.Peer-Reviewed Original ResearchConceptsCNI-free immunosuppressionCalcineurin inhibitor-free immunosuppressionMTOR inhibitorsFree immunosuppressionLung transplantationImproved survivalRapamycin inhibitorsNeurological diseasesSingle-center case-control studyCenter case-control studyCNI-free regimenCurative treatment optionGlomerular filtration rateMajority of patientsNon-malignant indicationsSignificant functional improvementCase-control studyMechanistic targetAcute rejectionLTx patientsNeurological complicationsAdult patientsMedian durationSingle centerTreatment options
2020
Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome
Morrone C, Smirnova NF, Jeridi A, Kneidinger N, Hollauer C, Schupp JC, Kaminski N, Jenne D, Eickelberg O, Yildirim AÖ. Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome. European Respiratory Journal 2020, 57: 2001416. PMID: 33303550, DOI: 10.1183/13993003.01416-2020.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBronchiolitis ObliteransBronchoalveolar Lavage FluidCathepsin BHumansLungLung TransplantationMiceConceptsBronchoalveolar lavage fluidCathepsin B activityHealthy donorsLung tissueCollagen depositionB activityCathepsin BBronchiolitis obliterans syndromeProgression of BOSFluorescence resonance energy transfer-based assayPromising therapeutic targetGrowth factor-β1Cathepsin B levelsSubsequent collagen depositionBOS pathogenesisBOS patientsBOS progressionLTx patientsLymphocytic bronchiolitisObliterans syndromeLung transplantationPeribronchial fibrosisPulmonary dysfunctionLung functionMajor complications